On diabetic foot ulcer knowledge gaps, innovation, evaluation, prediction markers, and clinical needs.

ABSTRACT: Diabetic foot ulcers (DFUs) remain a very prevalent and challenging complication of diabetes worldwide due to high morbidity, high risks of lower extremity amputation and associated mortality. Despite major advances in diabetes treatment in general, there is a paucity of FDA approved technologies and therapies to promote successful healing. Furthermore, accurate biomarkers to identify patients at risk of non-healing and monitor response-to-therapy are significantly lacking. To date, research has been slowed by a lack of coordinated efforts among basic scientists and clinical researchers and confounded by non-standardized heterogenous collection of biospecimen and patient associated data. Novel technologies, especially those in the single and 'multiomics' arena, are being used to advance th

SUBMITTER: Schmidt BM 

PROVIDER: S-EPMC10087892 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature